Hui-Di Jiang

Dr. Hui-Di Jiang

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2014 in Current Drug Metabolism
Verified
Journal Article
Closed access
ZCZhongjian Chen
Zhongjian Chen
SZShirui Zheng
Shirui Zheng
LLLiping Li
Liping Li
Hui-Di JiangHui-Di Jiang
Hui-Di Jiang
Flavonoids are naturally occurring polyphenols, which are widely taken in diets, supplements and herbal medicines. Epidemiological studies have shown a flavonoid-rich diet is associated with the decrease in incidence of a range of diseases. Pharmacological evidences also reveal flavonoids display anti-oxidant, anti-allergic, anti-cancer, anti-inflammatory, anti-microbial and anti-diarrheal activities. Therefore, it is critical to study the biotransformation and disposition of flavonoids in human. This review summarizes the major metabolism pathways of flavonoids in human. First, lactase-phlorizin hydrolase (LPH) and human intestinal microflora mediate the hydrolysis of flavonoid glycosides, which is recognized as the first and determinant step in the absorption of flavonoids. Second, phase II metabolic enzymes (UGTs, SULTs and COMT) dominate the metabolism of flavonoids in vivo. UGTs are the most major contributors, followed by SULTs and COMT. By contrast, phase I metabolism pathway mediated by CYPs only plays a minor role. Third, the coupling of transporters (such as BCRP and MRPs) and phase II enzymes (UGTs and SULTs) plays an important role in the disposition of flavonoids, especially in the enteroenteric and enterohepatic circulations. Thus, all the above factors should be taken into consideration when studying pharmacokinetics of flavonoids. Here we describe a comprehensive metabolism profile of flavonoids, which will enhance our understanding of the mechanisms underlying the disposition and pharmacological effects of flavonoids in vivo.

1 December 2012 in Fitoterapia
Verified
Journal Article
Closed access
ZCZhongjian Chen
Zhongjian Chen
SKSisi Kong
Sisi Kong
FSFeifeng Song
Feifeng Song
LLLiping Li
Liping Li
Hui-Di JiangHui-Di Jiang
Hui-Di Jiang

5 December 2007 in Journal of Agricultural and Food Chemistry
Verified
Journal Article
Closed access
PZPing Zhou
Ping Zhou
LLLi-Ping Li
Li-Ping Li
SLShu-Qing Luo
Shu-Qing Luo
Hui-Di JiangHui-Di Jiang
Hui-Di Jiang
SZSu Zeng
Su Zeng

10 July 2018 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
FSFeifeng Song
Feifeng Song
YYYaodong Yi
Yaodong Yi
CLCui Li
Cui Li
YHYongjun Hu
Yongjun Hu
JWJinhai Wang
Jinhai Wang
Hui-Di JiangHui-Di Jiang
Hui-Di Jiang
The peptide/histidine transporter SLC15A3 is responsible for transporting histidine, certain dipeptide and peptidomimetics from inside the lysosome to cytosol. Previous studies have indicated that SLC15A3 transcripts are mainly expressed in the lymphatic system, however, its regulation and biological role in innate immune responses and inflammatory diseases are as yet unknown. In this study, mouse peritoneal macrophages (PMs), mouse bone marrow-derived macrophages (BMDMs), the human acute monocytic leukemia cell line THP-1 and the human lung epithelial carcinoma cell line A549 were used to investigate the regulation and biological role of SLC15A3 in TLR-mediated inflammatory responses. Our results showed that SLC15A3 was upregulated by TLR2, TLR4, TLR7 and TLR9 ligands in macrophages at both the mRNA and protein levels via activation of NF-κB (nuclear factor-kappa-B), MAPK (mitogen-activated protein kinase) and IRF3 (interferon regulatory factor 3). Furthermore, knockdown or overexpression of SLC15A3 influenced the TLR4-triggered expression of proinflammatory cytokines. A reporter gene assay showed that the SLC15A3 promotor contained potential NF-κB binding sites, which were reasonable for regulating SLC15A3 by TLR-activation through NF-κB signaling. Additionally, SLC15A3 expression was increased and positively related to inflammation in mice with bacterial peritonitis. The collective findings suggest that SLC15A3 is regulated by various TLRs, and that it plays an important role in regulating TLR4-mediated inflammatory responses.

1 March 2014 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Closed access
SSSiyuan Sun
Siyuan Sun
KWKai Wang
Kai Wang
HLHongmei Lei
Hongmei Lei
LLLiping Li
Liping Li
MTMeijuan Tu
Meijuan Tu
Hui-Di JiangHui-Di Jiang
Hui-Di Jiang

15 July 2018 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
YHYongjun Hu
Yongjun Hu
FSFeifeng Song
Feifeng Song
Hui-Di JiangHui-Di Jiang
Hui-Di Jiang
GNGabriel Nuñez
Gabriel Nuñez
DSDavid Smith
David Smith
There is increasing evidence that proton-coupled oligopeptide transporters (POTs) can transport bacterially derived chemotactic peptides and therefore reside at the critical interface of innate immune responses and regulation. However, there is substantial contention regarding how these bacterial peptides access the cytosol to exert their effects and which POTs are involved in facilitating this process. Thus, the current study proposed to determine the (sub)cellular expression and functional activity of POTs in macrophages derived from mouse bone marrow and to evaluate the effect of specific POT deletion on the production of inflammatory cytokines in wild-type, Pept2 knockout and Pht1 knockout mice. We found that PEPT2 and PHT1 were highly expressed and functionally active in mouse macrophages, but PEPT1 was absent. The fluorescent imaging of muramyl dipeptide–rhodamine clearly demonstrated that PEPT2 was expressed on the plasma membrane of macrophages, whereas PHT1 was expressed on endosomal membranes. Moreover, both transporters could significantly influence the effect of bacterially derived peptide ligands on cytokine stimulation, as shown by the reduced responses in Pept2 knockout and Pht1 knockout mice as compared with wild-type animals. Taken as a whole, our results point to PEPT2 (at plasma membranes) and PHT1 (at endosomal membranes) working in concert to optimize the uptake of bacterial ligands into the cytosol of macrophages, thereby enhancing the production of proinflammatory cytokines. This new paradigm offers significant insight into potential drug development strategies along with transporter-targeted therapies for endocrine, inflammatory, and autoimmune diseases.